AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-26. (canceled)

27. (previously presented) A method for the treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody wherein said antibody is raised against a protofibril comprising an Aβ-Arc peptide selected from the group consisting of Aβ39-Arc (Amino Acids 1-39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1-40 of SEQ ID NO: 1), and Aβ42-Arc (SEQ ID NO: 1), wherein said antibodies bind to arctic and wild-type Aβ peptides in protofibril conformation.

28-43. (canceled)

44. (previously presented) A method for the treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a protofibril comprising an Aβ-Arc peptide selected from the group consisting of Aβ39-Arc (Amino Acids 1-39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1-40 of SEQ ID NO:1), Aβ41-Arc (Amino Acids 1-41 of SEQ ID NO:1), Aβ42-Arc (SEQ

ID NO:1), and combinations thereof, wherein said antibodies bind to arctic and wild-type Aβ peptides in protofibril conformation.

45. (previously presented) The method according to claim 44, wherein said protofibril further comprises an Aβ peptide having a mutation selected from the group consisting of the Dutch, Flemish, Italian, Iowa mutations, and combinations thereof.

46-48. (canceled)

49. (previously presented) The method according to claim 44, wherein said antibody is monoclonal.

50. (previously presented) The method according to claim 44, wherein said antibody is human or humanized.

51. (currently amended) A method for the treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a composition comprising a protofibril comprising an Aβ-Arc peptide selected from the group consisting of Aβ39-Arc (Amino Acids 1-39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1-40 of SEQ ID NO:1), Aβ41-Arc (Amino Acids 1-41 of SEQ ID NO:1), Aβ42-Arc (SEQ ID NO:1), and combinations thereof, wherein said antibodies bind to arctic and wild-type Aβ peptides in protofibril conformation.

52. (previously presented) The method according to claim 44, wherein said protofibril further comprises an Aβ peptide having a Dutch mutation.

53-56. (canceled)

57. (previously presented) The method according to claim 44, wherein said Aβ-Arc peptide is Aβ39-Arc (Amino Acids 1-39 of SEQ ID NO:1).

58. (previously presented) The method according to claim 44, wherein said Aβ-Arc peptide is Aβ40-Arc (Amino Acids 1-40 of SEQ ID NO:1).

59. (previously presented) The method according to claim 44, wherein said Aβ-Arc peptide is Aβ41-Arc (Amino Acids 1-41 of SEQ ID NO:1).

60. (previously presented) The method according to claim 44, wherein said Aβ-Arc peptide is Aβ42-Arc (SEQ ID NO:1).

61. (new) The method according to claim 51, wherein said antibody is monoclonal.

62. (new) The method according to claim 51, wherein said antibody is human or humanized.

63. (new) The method according to claim 51, wherein said protofibril further comprises an Aβ peptide with a mutation selected from the group consisting of the Dutch, Flemish, Italian and Iowa mutations.

64. (new) The method according to claim 51, wherein said Aβ-Arc peptide is Aβ39-Arc (Amino Acids 1-39 of SEQ ID NO:1).

65. (new) The method according to claim 51, wherein said Aβ-Arc peptide is Aβ40-Arc (Amino Acids 1-40 of SEQ ID NO:1).

66. (new) The method according to claim 51, wherein said Aβ-Arc peptide is Aβ42-Arc (SEQ ID NO:1).

67. (new) The method according to claim 51, wherein said Aβ-Arc peptide is Aβ41-Arc (Amino Acids 1-41 of SEQ ID NO:1).